Creating a story on the pages of a book about diffuse B-large cell lymphoma

Abstract

Within the framework of VI All-Union Congress of Hematologists of Russia and III Congress of Transfusiologists of Russia, the symposium concerning diffuse large B cell lymphoma (DLBCL) was held on April 21. Leading Russian experts discussed current trends in diagnosis, the causes of the failures and successes of the treatment of this heterogeneous disease, the changes that are expected in the very near future. During the symposium, the detailed data concerning the new option for DLBCL therapy polatuzumab vedotin (immunoconjugate) were also presented. The symposium was supported by Roche.